Compare CLFD & IPSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CLFD | IPSC |
|---|---|---|
| Founded | 1979 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Medicinal Chemicals and Botanical Products |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 407.8M | 367.6M |
| IPO Year | 1995 | 2021 |
| Metric | CLFD | IPSC |
|---|---|---|
| Price | $31.83 | $1.89 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | ★ $43.50 | $4.25 |
| AVG Volume (30 Days) | 136.2K | ★ 406.0K |
| Earning Date | 05-06-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 31.76 | ★ 91.30 |
| EPS | ★ 0.14 | N/A |
| Revenue | $85,034,000.00 | ★ $109,164,000.00 |
| Revenue This Year | $11.64 | N/A |
| Revenue Next Year | $22.30 | N/A |
| P/E Ratio | $220.57 | ★ N/A |
| Revenue Growth | 9.51 | ★ 1556.76 |
| 52 Week Low | $23.76 | $0.44 |
| 52 Week High | $52.73 | $2.97 |
| Indicator | CLFD | IPSC |
|---|---|---|
| Relative Strength Index (RSI) | 57.29 | 44.42 |
| Support Level | $27.95 | $1.92 |
| Resistance Level | $33.27 | $2.39 |
| Average True Range (ATR) | 0.89 | 0.10 |
| MACD | 0.35 | -0.01 |
| Stochastic Oscillator | 89.28 | 31.34 |
Clearfield Inc designs, manufactures, and distributes fiber protection, fiber management, and fiber delivery solutions to enable rapid and cost-effective fiber-fed deployment throughout the broadband service provider space prominently across North America. Its 'fiber to anywhere' platform serves the requirements of Community Broadband customers, Multiple System Operators, Large Regional Service Providers, National Carriers, and International customers (including Europe, Canada, Mexico, and Caribbean Markets). Its product offerings include Accessories, Cassettes, Cable & Drop Assemblies, Frames & Panels, Microducts, Optical Components, etc. The company derives the majority of its revenue from the United States.
Century Therapeutics Inc is a biotechnology company harnessing the power of allogeneic pluripotent stem cell therapies to develop potentially curative cell therapy products for autoimmune diseases, including type 1 diabetes, or T1D, and cancer. Its beta islet, T cell and NK cell programs are allogeneic, meaning it is derived from healthy donors for use in any patient, rather than being sourced from an individual for their own specific use, as is the case with autologous T cells. The cell types it can generate from iPSCs, including iPSC-derived beta islet cells, iPSC-derived CD4+ and CD8+ alphabeta T cells, or alphabeta iT cells, and iPSC- natural killer cells, or iNK cells.